Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Companies

Mundipharma International

Mundipharma International seeks products in analgesia, anesthesia and oncology to market through a pan-European sales force.

The company in detail

Profile

Mundipharma International Limited undertakes licensing and business development activities in support of the Purdue/Mundipharma/Napp independent associated companies, which offer pan-European sales and marketing capabilities. The companies have grown remarkably in recent years as they respond successfully to the rapidly evolving healthcare market by virtue of an entrepreneurial outlook and differentiated products. Sales and Marketing Overview The Purdue/Mundipharma/Napp independent associated companies are world leaders in the development of strong analgesics for the treatment of severe pain. They are worldwide leaders in the opioid analgesic market, with products such as OxyContin (oxycodone), MST Continus (morphine), Palladone (hydromorphone), Sevredol (morphine), and Tramadol. Many of these products are delivered through patented, controlled release technologies developed in-house. The companies' products are primarily branded ethical medicines. Product sales are made in 113 countries around the world and are supported by a strong, worldwide sales and marketing operation that comprises over 1000 field sales representatives in Europe. The companies are committed to extending their presence in the areas of analgesia, anaesthesia and oncology, based on considerable expertise in treating patients with pain and cancer. Research & Development Overview Staff are employed across R&D establishments in five countries (US, UK, Germany, Canada and Switzerland), providing a full spectrum of R&D activities from preclinical research to clinical development and registration. A substantial medical research and regulatory affairs function is located in Cambridge, UK, with expertise in handling European clinical research and worldwide product registrations. Since 1990, around 590 product registrations have been achieved in 102 territories, including a significant number of registrations under the Mutual Recognition Procedure. These services can be made available to partners in order to expedite rapid and effective progress of drugs in clinical stage development.

Partnering strategy/interests

Business Development Overview Mundipharma International Limited is actively seeking products and commercial partnerships to complement our product portfolio and sales and marketing expertise in the areas of pain, oncology and supportive care as outlined in the "Partnering Strategy" profiles below. Within Europe, products are marketed throughout the European Economic area via a network of companies including Napp Pharmaceuticals, Mundipharma and Norpharma. Extension of the sales and marketing coverage into Eastern Europe beyond the enlarged EU is a current priority. A successful record in the marketing of ethical pharmaceuticals, both in-licensed and in-house, underlies the companies' capabilities in successful commercialisation of products falling both within and outside these specified therapeutic areas.

In-licensing

Therapeutic drugs in late stage development (marketed, registered or in clinical trials) are sought to complement our product portfolio. More
Novel, late stage therapeutics are sought for marketing through a Europe wide specialist sales force. More

Deals

To view this information, you must subscribe to Partneringtools.

Press Releases

(27th Jun 2006) Sosei today announces that it has entered into an agreement with Mundipharma International for the development and commercialisation of AD 923, Sosei's novel sublingual fentanyl spray for cancer breakthrough pain, in Europe and other markets. More
(2nd Feb 2006) BioCryst and Mundipharma to develop and commercialize Fodosine™ in markets across Europe, Asia and Australasia for use in oncology. More
(13th Aug 2003) SkyePharma PLC licenses European marketing and distribution rights for DepoCyte, a treatment for lymphomatous meningitis, to Mundipharma More

Head office

Mundipharma International
Cambridge Science Park
Milton Road
Cambridge
CB4 0GW
United Kingdom

Tel:  +44 1223 42 42 11
www | email

Contact details

Dr. John Roe
Senior Business Development Manager
Request more information
Dr Charlie Bailey
Business Development Manager
Request more information
Mr Simon Bashforth
Managing Director
Request more information
Mr Åke Wikström
Regional Director, Europe
Request more information

Company figures

Formed: 1952
Annual Turnover: $2.3bn global sales (2005)
Number of employees: 3000

Regional and subsidiary offices

Mundipharma A/S
Vollsveien 13C
1366 Lysaker
Norway

email
Mundipharma AB
Molndalsvagen 26
Gothenburg
Sweden

Tel:  +46 31 335 81 20
email
Mundipharma CVA
Campus Mechelen
Schaliënhoevedreef 20/H
B-2800 MECHELEN
Belgium

Tel:  + 32 15 45 11 80
email
Mundipharma Farmaceutica Lda
Lisbon
Portugal

email
Mundipharma GesmbH
Apollogasse 16-18
Wien
Austria

Tel:  +43 1 523 2505
email
Mundipharma GmbH
Mundipharma Strasse 2
LIMBURG (Lahn)
Germany

Tel:  +49 6431 7010
www | email
Mundipharma Medical Company
St Alban-Rheinweg 74
Basel
Switzerland

Tel:  +41 61 205 1111
www | email
Mundipharma OY
Rajatorpantie 41B
Vantaa
Finland

Tel:  +358 9 8520 2065
email
Mundipharma Pharmaceutical Company
54 Fitzwilliam Square
Dublin
Ireland

Tel:  +353 166 12115
email
Mundipharma Pharmaceuticals Ltd.
13 Othellos Street
1685 Nicosia
Cyprus

email
Mundipharma Pharmaceuticals SL
López de Aranda, 35
E-28027
Madrid
Spain

email
Mundipharma Pharmaceuticals Srl
Via Vincenzo Monti 8
Milano
Italy

email
Mundipharma Pharmeceuticals BV
Astronaut 36
Amersfoot
Netherlands

Tel:  +31 33 450 82 70
email
Mundipharma Polska Sp
Ul. Poleczki 12
02-822 Warszawa
Poland

email
Mundipharma SARL
42 Rue D'aguesseau
Paris
France

Tel:  +33 1 5538 9230
email
Napp Pharmaceuticals Ltd
Cambridge Science Park
Cambridge
United Kingdom

Tel:  +44 1223 424 444
www | email
Norpharma A/S
Slotsmarken 17
Horsholm
Denmark

Tel:  +45 45 174 800
email

Related categories

Partnering consultation free of charge
Profile your company today
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us